Cryoport, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cryoport, Inc. on August 24, 2018. The filing reports the entry into a material definitive agreement to establish an equity offering program.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or margin data. The primary financial metric disclosed is the authorization to sell shares of common stock with an aggregate offering price of up to $35,000,000.
Material Changes and Agreements
- Sales Agreement: On August 24, 2018, the Company entered into a Sales Agreement with Jefferies LLC.
- Program Type: An "at the market" equity offering program allowing the Company to sell shares from time to time.
- Compensation: Jefferies LLC will receive a commission of 3.0% of the gross sales price of all shares sold under the agreement.
- Registration: Shares will be issued pursuant to an effective shelf registration statement on Form S-3 (File No. 333-215776).
- Termination: Either party may terminate the agreement upon ten days' written notice.
Guidance, Outlook, and Risks
The filing includes forward-looking statements regarding the ability to sell shares and raise funds. Management notes that actual results may differ due to market conditions and pre-sale conditions. The Company explicitly states it has no obligation to sell any shares and may suspend the program at any time. Risks include the occurrence of a material adverse change in the Company, which could allow Jefferies to terminate the agreement.
Investor Verification Checklist
- Verify the current market price of Cryoport common stock to assess the potential dilution impact of a $35 million offering.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific limitations on daily sales volume and minimum price thresholds.
- Confirm the status of the underlying Form S-3 shelf registration statement.
- Monitor future filings for actual sales activity and proceeds raised under this program.